The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Management of Bone Metastases
Open accessAbstract
Metastatic bone disease develops as a result of the many interactions between tumor cells and bone cells. This leads to disruption of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types providing a rational target for treatment. The clinical course of metastatic bone disease in multiple myeloma, breast and prostate cancers is relatively long, with patients experiencing sequential skeletal complications over a period of several years. These include bone pain, fractures, hypercalcemia, and spinal cord compression, all of which may profoundly impair a patient's quality of life. External beam radiotherapy and systemic endocrine and cytotoxic treatments are the mainstay of treatment in advanced cancers. However, it is now clear that the bisphosphonates provide an additional treatment strategy, which reduces both the symptoms and complications of bone involvement. Additionally, new specific molecules such as osteoprotogerin have been developed that are based on our improved understanding of the cellular signaling mechanisms involved in cancer-induced bone disease. These potent molecules are now entering clinical trials. Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate in metastatic bone disease and its use in the prevention and treatment of osteoporosis in cancer patients. In vitro suggestions of direct anticancer activity and some promising clinical data in early breast cancer have resulted in considerable interest in the possible adjuvant use of bisphosphonates to inhibit the development of bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Cited by
Bone Imaging in Metastatic Breast Cancer
Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.181 · Cited by 656
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Genes Associated With Breast Cancer Metastatic to Bone
Smid, M., Wang, Y., Klijn, J. G. M., Sieuwerts, A. M., Zhang, Y., Atkins, D., Martens, J. W. M., & Foekens, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8802 · Cited by 314
Price, J. T., Quinn, J. M. W., Sims, N. A., Vieusseux, J., Waldeck, K., Docherty, S. E., Myers, D., Nakamura, A., Waltham, M. C., Gillespie, M. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4458 · Cited by 142
Metadata
- Authors
- Coleman, R. E.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 5
- Issue
- 6
- Pages
- 463-470
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2119263434
- Cited by
- 162
- References
- 1
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Bone Metastases. https://app.cochat.ai/papers/10.1634/theoncologist.5-6-463
- The paper
- Coleman, R. E. (2000). Management of Bone Metastases. The Oncologist. https://doi.org/10.1634/theoncologist.5-6-463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.